IE
SPRY icon

Israel Englander’s ARS Pharmaceuticals SPRY Stock Holding History

Israel Englander’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$961K Buy
+120,000
New +$1.03M ﹤0.01% 4338

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Israel Englander's SPRY Position: Q2 2026 in Review

Israel Englander reduced its ARS Pharmaceuticals (SPRY) stake by 60% in Q2 2026, selling an estimated $30.8M and leaving 2,400,937 shares worth $19.2M. The position accounts for 0.01% of the portfolio, ranked #1667.

Israel Englander first reported a position in SPRY in Q4 2020 and has held it in 18 quarters since. The position peaked at $48M in Q1 2026. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Israel Englander held 2,400,937 shares of ARS Pharmaceuticals worth $19.2M as of Q2 2026.
  • Israel Englander sold 3,581,982 ARS Pharmaceuticals shares in Q2 2026, an estimated $30.8M.
  • ARS Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1667 holding.
  • Israel Englander first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 18 quarters since.
  • Israel Englander's ARS Pharmaceuticals position peaked at $48M in Q1 2026.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.